Dear DCI Community Members,
We are delighted to share the latest developments of the DCI Network with you!
The DCI Network successfully hosted a webinar, The Future of Electronic Medication Label and Patient Communication.
Panelists:
Patient Advocacy View - Stephanie Walker, Retired Registered Nurse; Member, MBC Alliance Executive Group; Project Lead, BECOME initiative
Patient Advocacy View - Claire Saxton, Vice President, Patient Experience, Cancer Support Community
Pharmaceutical Industry View - Dr. Shimon Yoshida, Executive Director, Head of International Labeling Group, Pfizer
Pharmaceutical Industry View - Craig Anderson, Director, Information Management, Pfizer
Moderator:
Dr. Yuri Quintana, Chief, Division of Clinical Informatics, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School
Recording and slides of this webinar are available through the event page: https://www.dcinetwork.org/events/176.
Please visit https://www.dcinetwork.org/events to sign up for future webinars and watch the recordings of our recently hosted webinars.
Platinum Events:
The DCI Network Retreat will be held at the Harvard Faculty Club in Boston, MA on June 22nd, 2023. The retreat will discuss the results of the first year of the Network and its future directions.
More information about the Retreat is available here: https://www.dcinetwork.org/events/139.
Invitation will be limited to platinum members only. For more information on how to become a member, please see: https://www.dcinetwork.org/about-us/membership-levels.
Working Groups:
DCI Network's first Working Group on Real World Evidence has been created.
Vision
To create a learning health system that accelerates how we implement collaborative precision oncology so that we can tailor care to each patient’s clinical history, genomics, geography, and social determinants of health such as race, gender, sexual orientation, economic status, education, access to care, neighborhood effects and social support.
Objective
Create methods and operational examples of how real-world data (RWD) can be collected, aggregated, and analyzed to create standards-based approaches for improving biomedical discoveries and clinical decision-making to facilitate collaborative precision oncology.
Problem Statement
Precision oncology requires voluminous longitudinal data to identify mechanisms of disease, new therapies, and new treatment paradigms. Individual institutions have limited resources or funding needed to accomplish this objective. By employing multidisciplinary perspectives, novel concepts, and patient diversity, we can address these challenges. We aim to identify best practices and methods that incentivize participation in collaborative precision oncology on a national and international scale. Some of the key challenges are:
- How to capture and represent screening, referral patterns to care, and social determinants of health?
- How do digitally represent therapeutic protocols and therapeutic combinations, adherence, and reasons for changes to the care plans?
- How to analyze similar patients, therapeutic combinations, and differences in short- and long-term outcomes?
- What new governance and engagement models are needed to incentivize participation across institutions?
- What are sustainable business models that incentivize collaborative participation?
Why is this needed?
Misaligned incentives are impediments to obtaining, curating, aggregating, and analyzing the data. While there are many standards and data models, they are not being used consistently. Some data models do not represent information at the granularity needed to answer complex questions. We aim to identify the best standards and data models, add to them, and incentivize adoption. A harmonized collaborative approach is needed that includes:
- A common data model: A common, standards-based data model that is sufficiently specific and granular to answer key questions not being answered well by today’s data repositories.
- Scalable architecture that can be implemented locally and integrated nationally at feasible costs.
- A workable governance model and business model that builds trust and incentivizes the participation of institutions and patients and promotes sustainability.
To request to join the working group, please contact Yuri Quintana, Ph.D. at yquintan@bidmc.harvard.edu, and Gyana Srivastava at gsrivast@bidmc.harvard.edu.
Explore the other exciting aspects of DCI Network website:
See the latest news headlines, updated daily. You can also set-up to receive a daily or weekly digest here: https://www.dcinetwork.org/mydcinetwork
Real-World Evidence:
- FDA Seeks Input on Advancing Use of Real-World Data and Evidence
- How Real-World Evidence Helps Medical Device Manufacturers Drive Value
- International collaboration - advancing the use of real-world evidence in health technology assessment
Clinical Trials:
- Clinical Trials: An Evolutionary Perspective
- How Will FDA Guidance Impact Decentralized Clinical Trials in 2023?
Health Disparities:
- Why doctors say breast cancer screenings need to happen at a younger age, especially for Black people
- Black, Hispanic patients with cancer more likely to report negative care experiences, bias
- Racial Disparities Among US Neighborhoods May Have Implications for Health Outcomes
Artificial Intelligence:
Telehealth:
- Executive Summary: Tracking Telehealth Changes State-by-State in Response to COVID-19 - January 2023
Explore our Library:
- Empowering clinical research in a decentralized world
- Medicine of the future: How and who is going to treat us?
- The next generation of evidence-based medicine
Explore our directory of Companies and Non-Profit Organizations in the health care.
Explore other members in our directory that are a part of the DCI Network.
About the DCI Network:
Launched in September 2022, the DCI Network aims to accelerate solutions to complex healthcare problems by creating new multi-stakeholder alliances and consortia, and creating strategic roadmaps to implement solutions that scale. The DCI Network brings together top thought leaders and decision-makers from leaders from major biopharmaceutical companies, high-tech companies, healthcare providers, academic centers, and non-profit groups. Members are C-Suite leaders (CEO, CIO, CMIO) from non-profits, the private sector, academics, government, patients, and advocates dedicated to collaborative approaches to medicine and science.
The Division of Clinical Informatics (DCI) at Beth Israel Deaconess Medical Center (BIDMC) is a leading center for developing scalable models, informatics research, and policy-making since 1970.
Learn more about our membership levels and join the DCI Network to stay current on emerging trends and join the discussion with thought leaders.
To learn more, visit https://www.dcinetwork.org/about-us.
For more information, contact Dr. Yuri Quintana at yquintan@bidmc.harvard.edu.
Yuri Quintana, Ph.D. (He/Him/His)
Chief, Division of Clinical Informatics, Beth Israel Deaconess Medical Center
Assistant Professor of Medicine, Harvard Medical School
